Skip to main content

Advertisement

Log in

Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Two recent South Korean studies showed adjuvant therapy (AT) was not associated with improved survival in pT1N1 gastric adenocarcinoma (GAC). We established the prognostic utility of lymph node status, determined the pattern of use of AT, and compared survival stratified by type of AT in pT1N1 GAC in a Western patient population.

Methods

We identified patients with pT1N0 and pT1N1 GAC using the National Cancer Database from 2004 to 2012. Clinicopathologic variables, treatment regimens, and overall survival (OS) were compared.

Results

We compared 4516 (86.6%) pT1N0 to 696 (13.4%) pT1N1 patients. pT1N1 tumors were larger (median size 2.5 vs. 1.8 cm, p < 0.001), more often poorly differentiated (56.2% vs. 39.6%, p < 0.001), and had higher median retrieved lymph nodes (RLN) (14 vs. 12, p < 0.001) compared with pT1N0. pT1N1 was associated with worse median overall survival (OS) (6.9 vs. 9.9 years for pT1N0, p < 0.001). pN1 was independently associated with worse OS (hazard ratio [HR] 2.17, 95% confidence interval [CI] 1.84–2.56). Increased RLN was associated with improved OS (HR 0.73, 95% CI 0.65–0.83). Among pT1N1 patients, 330 (47.4%) had observation (OBS), 77 (11.1%) received adjuvant chemotherapy (ACT), 68 (9.8%) received adjuvant radiation therapy (ART), and 221 (31.8%) received adjuvant chemoradiation therapy (ACRT). ACT and ACRT were independently associated with improved OS (HR 0.37, 95% CI 0.22–0.65 and HR 0.40, 95% CI 0.28–0.57).

Conclusions

pN1 was associated with worse survival and RLN ≥ 15 was associated with improved survival in pT1 GAC. ACT and ACRT were independently associated with improved survival in pT1N1 gastric cancer suggesting a valuable role in Western patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  2. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.

    Article  CAS  PubMed  Google Scholar 

  3. National Comprehnsive Cancer Network. National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2018 GC).

  4. Kim SM, An JY, Lee J, Sohn TS, Kim S. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. Ann Surg Oncol. 2018;25:1616–24.

    Article  PubMed  Google Scholar 

  5. Shin HB, An JY, Lee SH, et al. Is adjuvant chemotherapy necessary in pT1N1 gastric cancer? BMC Cancer. 2017;17:287.

    Article  PubMed  PubMed Central  Google Scholar 

  6. NCCN clinical practice guidelines in oncology, gastric cancer. 2017. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 12 Oct 2017.

  7. Association JGC. Japanese Gastric Cancer Treatment Guidelines 2010 (Version 3). Gastric Cancer. 116:5592–8.

  8. Merchant SJ, Li L, Kim J. Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique? World J Gastroenterol. 2014;20:11546–51.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol. 2010;21:152–60.

    Article  CAS  PubMed  Google Scholar 

  10. Nelson R, Ko EB, Arrington A, et al. Race and correlations between lymph node number and survival for patients with gastric cancer. J Gastrointest Surg. 2013;17:471-81.

    Article  PubMed  Google Scholar 

  11. American College of Surgeons: National cancer database. 1996–2017. Available at: https://www.facs.org/quality-programs/cancer/ncdb. Accessed 7 Sept. 2017.

  12. Wu CW, Hsieh MC, Lo SS, et al. Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci 1997;42:1265–9.

    Article  CAS  PubMed  Google Scholar 

  13. Zhou Y, Yu F, Wu L, Ye F, Zhang L, Li Y. Survival after gastrectomy in node-negative gastric cancer: a review and meta-analysis of prognostic factors. Med Sci Monit. 2015;21:1911–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219–25.

    Article  Google Scholar 

  15. Roviello F, Rossi S, Marrelli D, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol. 2006;94:275–80; discussion 4.

    Article  PubMed  Google Scholar 

  16. Marrelli D, Pedrazzani C, Corso G, et al. Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg. 2009;250:43–50.

    Article  PubMed  Google Scholar 

  17. Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol. 2016;22:2875–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li F, Zhang R, Liang H, Liu H, Quan J. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol. 2013;107:130–5.

    Article  PubMed  Google Scholar 

  19. Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kong SH, Lee HJ, Ahn HS, et al. Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Ann Surg. 2012;255:50–8.

    Article  PubMed  Google Scholar 

  21. Kim YI. Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer? Ann Surg Treat Res. 2014;87:180-4.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980-2014. JAMA. 2017;317:388–406.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Nassour I, Fullington H, Hynan LS, et al. The yield of staging laparoscopy in gastric cancer is affected by racial and ethnic differences in disease presentation. Ann Surg Oncol. 2017;24:1787–94.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Choi IJ, Lee JH, Kim YI, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. Gastrointest Endosc. 2015;81:333-41 e1.

    Article  PubMed  Google Scholar 

  25. Sekiguchi M, Suzuki H, Oda I, et al. Favorable long-term outcomes of endoscopic submucosal dissection for locally recurrent early gastric cancer after endoscopic resection. Endoscopy. 2013;45:708–13.

    Article  PubMed  Google Scholar 

  26. Kim MY, Cho JH, Cho JY. Ever-changing endoscopic treatment for early gastric cancer: yesterday-today-tomorrow. World J Gastroenterol. 2014;20:13273–83.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kitagawa Y, Fujii H, Kumai K, et al. (2005) Recent advances in sentinel node navigation for gastric cancer: a paradigm shift of surgical management. J Surg Oncol. 90:147–51.

    Article  PubMed  Google Scholar 

  28. Kelder W, Nimura H, Takahashi N, Mitsumori N, van Dam GM, Yanaga K. Sentinel node mapping with indocyanine green (ICG) and infrared ray detection in early gastric cancer: an accurate method that enables a limited lymphadenectomy. Eur J Surg Oncol. 2010;36:552–8.

    Article  CAS  PubMed  Google Scholar 

  29. Sanjeevaiah A, Cheedella N, Hester C, Porembka MR. Gastric cancer: recent molecular classification advances, racial disparity, and management implications. J Oncol Pract. 2018;14:217–24.

    Article  PubMed  Google Scholar 

  30. Rajabi B, Corral JC, Hakim N, Mulla ZD. Descriptive epidemiology of gastric adenocarcinoma in the state of Texas by ethnicity: Hispanic versus white non-Hispanic. Gastric Cancer. 2012;15:405–13.

    Article  PubMed  Google Scholar 

  31. Wu X, Chen VW, Andrews PA, Ruiz B, Correa P. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control. 2007;18:585–93.

    Article  PubMed  Google Scholar 

  32. Wu X, Chen VW, Ruiz B, Andrews P, Su LJ, Correa P. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer. 2006;106:683–92.

    Article  PubMed  Google Scholar 

  33. Howard JH, Hiles JM, Leung AM, Stern SL, Bilchik AJ. Race influences stage-specific survival in gastric cancer. Am Surg. 2015;81:259–67.

    PubMed  Google Scholar 

  34. Fukuhara S, Yabe M, Montgomery MM, Itagaki S, Brower ST, Karpeh MS, Jr. Race/Ethnicity is predictive of lymph node status in patients with early gastric cancer. J Gastrointest Surg. 2014;18:1744–51.

    Article  PubMed  Google Scholar 

  35. Chen Y, Haveman JW, Apostolou C, Chang DK, Merrett ND. Asian gastric cancer patients show superior survival: the experiences of a single Australian center. Gastric Cancer. 2015;18:256–61.

    Article  PubMed  Google Scholar 

  36. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73.

    Article  CAS  PubMed  Google Scholar 

  37. Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. Ann Surg Oncol. 2010;17:4–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Sam C. Wang is supported by the University of Texas Southwestern Medical Center Disease-Oriented Clinical Scholarship. Matthew R. Porembka is a Dedman Family Scholar in Clinical Care.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matthew R. Porembka MD.

Ethics declarations

Disclosures

No financial or commercial disclosures.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 46 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hester, C.A., Augustine, M.M., Mansour, J.C. et al. Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population. Ann Surg Oncol 26, 167–176 (2019). https://doi.org/10.1245/s10434-018-6995-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6995-3

Keywords

Navigation